BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Trop2 Adc Sacituzumab Tirumotecan Approved For Marketing For Fourth Indication By China's NMPA

Reuters
Feb 06
BRIEF-<a href="https://laohu8.com/S/002422">Sichuan Kelun</a>-Biotech Biopharmaceutical Says Trop2 Adc Sacituzumab Tirumotecan Approved For Marketing For Fourth Indication By China's NMPA

Feb 6 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:

  • TROP2 ADC SACITUZUMAB TIRUMOTECAN APPROVED FOR MARKETING FOR FOURTH INDICATION BY NMPA

Further company coverage: 6990.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10